Home/Filings/4/0001731122-25-000655
4//SEC Filing

Boenisch Sandra 4

Accession 0001731122-25-000655

CIK 0001314052other

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 8:00 PM ET

Size

5.7 KB

Accession

0001731122-25-000655

Insider Transaction Report

Form 4
Period: 2025-04-28
Boenisch Sandra
PFO & Treasurer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-04-28+12,50012,500 total
    Exercise: $8.57From: 2025-04-28Exp: 2033-03-31Common Stock (12,500 underlying)
Footnotes (1)
  • [F1]On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

Documents

1 file

Issuer

ANAVEX LIFE SCIENCES CORP.

CIK 0001314052

Entity typeother

Related Parties

1
  • filerCIK 0001655366

Filing Metadata

Form type
4
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 8:00 PM ET
Size
5.7 KB